Integrating lab data into business enterprise systems can drive both research processes and business decisions.
An experimental procedure that strengthens stem cells’ ability to regenerate damaged tissue could offer new hope to sufferers of muscle-wasting diseases such as myopathy and muscular dystrophy.
A Wyeth statement called the US Supreme Court’s ruling in Wyeth v. Levine "disappointing, not only for Wyeth, but for patients and public health in general".
Sepsis, a blood-borne bacterial infection, can kill as many as 60 percent of the people who contract it.
Cell-based toxicogenomics studies are emerging as an alternative to animal testing. But for now, animal models are the necessary choice.
In vitro toxicity testing has been used for many years, but the predictive power for either rodent, or human toxic liability has not been demonstrated, until recently.
A US Supreme Court ruling that federal approval of a drug is no protection from lawsuits in state courts could make drugmakers more cautious about safety issues and may lead them to halt development of some medicines.
In vivo imaging technology developers and providers gear new features toward the drug discovery and development process.
Researchers step up to multiplex bead-based platforms to detect proteins for target indentification through clinical analysis.
With a push to help clients get into the clinic faster and get their drugs on the market, contract formulators assist in all stages of the drug formulation process.
It took 13 years and nearly $3 billion to sequence the first single human genome, a proverbial lifetime and bank bailout away from the goal of a $1000 genome for an individual’s DNA sequence.
The Food and Drug Administration’s (FDA) approval of a clinical trial involving a human embryonic stem cell-based therapy is being hailed both as a triumph of science over politics, as well as heralding a much-needed financial shot in the arm for the nascent hESC biotech industry.
Lyophilization Services of New England, Inc. (LSNE) has provided CGMP contract manufacturing services since 1997.
A new discovery shows that cellular mechanisms used by the blind mole rat to survive the very low oxygen environment of its subterranean niche are the same as those that tumors use to thrive deep in our tissues.